You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNitroglycerin
Accession NumberDB00727  (APRD00153)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionA volatile vasodilator which relieves angina pectoris by stimulating guanylate cyclase and lowering cytosolic calcium. [PubChem]
Structure
Thumb
Synonyms
1,2,3-Propanetrioltrinitrate
1,2,3-Propanetriyl nitrate
Glycerin trinitrate
Glycerol trinitrate
Glycerol, nitric acid triester
Glyceroli trinitratis
Glyceroltrinitrat
Glyceryl trinitrate
Minitran
Natispray
NG
Nitro-dur
Nitroglicerina
Nitroglycerin
Nitroglycerine
Nitroglycerol
Nitrolingual
Nitromed
Nitromist
Nitrostat
Propane-1,2,3-triyl trinitrate
Rectogesic
Transderm nitro
Trinitrine
Trinitroglycerin
Trinitroglycerol
External Identifiers
  • DR 66
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GonitroPowder400 ug/gSublingualEspero Pharmaceuticals, Inc.2016-07-01Not applicableUs
MinitranPatch54 mgTransdermalValeant Canada Lp Valeant Canada S.E.C.1995-12-31Not applicableCanada
MinitranPatch18 mgTransdermalValeant Canada Lp Valeant Canada S.E.C.1995-12-31Not applicableCanada
MinitranPatch36 mgTransdermalValeant Canada Lp Valeant Canada S.E.C.1995-12-31Not applicableCanada
Minitran - Patch Trd 72mg/26.6 Sq CmPatch72 mgTransdermalGraceway PharmaceuticalsNot applicableNot applicableCanada
Mylan-nitro Patch 0.2Patch, extended release20.7 mgTransdermalMylan Pharmaceuticals Ulc2013-06-04Not applicableCanada
Mylan-nitro Patch 0.4Patch, extended release41.4 mgTransdermalMylan Pharmaceuticals Ulc2013-06-04Not applicableCanada
Mylan-nitro Patch 0.6Patch, extended release62.2 mgTransdermalMylan Pharmaceuticals Ulc2013-06-04Not applicableCanada
Mylan-nitro Patch 0.8Patch, extended release82.9 mgTransdermalMylan Pharmaceuticals Ulc2013-06-04Not applicableCanada
Mylan-nitro Sublingual SprayAerosol, metered0.4 mgSublingualMylan Pharmaceuticals Ulc2001-08-23Not applicableCanada
Nitro-durPatch160 mg/1TransdermalMerck Sharp & Dohme Corp.1995-04-04Not applicableUs
Nitro-durPatch80 mg/1TransdermalMerck Sharp & Dohme Corp.1995-04-04Not applicableUs
Nitro-durPatch20 mg/1TransdermalMerck Sharp & Dohme Corp.1995-04-04Not applicableUs
Nitro-durPatch120 mg/1TransdermalMerck Sharp & Dohme Corp.1995-04-04Not applicableUs
Nitro-durPatch40 mg/1TransdermalMerck Sharp & Dohme Corp.1995-04-04Not applicableUs
Nitro-durPatch60 mg/1TransdermalMerck Sharp & Dohme Corp.1995-04-04Not applicableUs
Nitro-dur 0.2Patch, extended release40 mgTransdermalMerck Canada Inc1991-12-31Not applicableCanada
Nitro-dur 0.3 - 60mg/15 Sq Cm, 0.3mg/hrPatch, extended release60 mgTransdermalKey Pharmaceuticals, Division Of Schering Plough Canada Inc.1996-09-052004-07-20Canada
Nitro-dur 0.4Patch, extended release80 mgTransdermalMerck Canada Inc1991-12-31Not applicableCanada
Nitro-dur 0.6Patch, extended release120 mgTransdermalMerck Canada Inc1991-12-31Not applicableCanada
Nitro-dur 0.8Patch, extended release160 mgTransdermalMerck Canada Inc1993-12-31Not applicableCanada
Nitrogard-SR Tab 1mgTablet, extended release1 mgBuccalAstra Pharma Inc.1987-12-311996-11-13Canada
NitroglycerinTablet, orally disintegrating.4 mg/1SublingualGreenstone LLC2003-04-08Not applicableUs
NitroglycerinAerosol, metered400 ug/1SublingualRouses Point Pharm2012-10-16Not applicableUs
NitroglycerinTablet, orally disintegrating.3 mg/1SublingualGreenstone LLC2003-04-08Not applicableUs
NitroglycerinTablet, orally disintegrating.4 mg/1SublingualPhysicians Total Care, Inc.2009-06-25Not applicableUs
NitroglycerinTablet, orally disintegrating.6 mg/1SublingualGreenstone LLC2003-04-08Not applicableUs
Nitroglycerin In DextroseInjection40 mg/100mLIntravenousBaxter Healthcare Company1989-12-29Not applicableUs
Nitroglycerin In DextroseInjection10 mg/100mLIntravenousBaxter Healthcare Company1989-12-29Not applicableUs
Nitroglycerin In DextroseInjection20 mg/100mLIntravenousBaxter Healthcare Company1989-12-29Not applicableUs
Nitroglycerin Inj 5mg/mlLiquid5 mgIntravenousDavid Bull Laboratories (Pty) Ltd.1988-12-312000-08-01Canada
Nitroglycerin Injection USPSolution5 mgIntravenousSandoz Canada Incorporated1993-12-31Not applicableCanada
Nitroglycerin LingualSpray400 ug/1OralJacksonville Pharmaceuticals, Inc.2016-03-01Not applicableUs
Nitroglycerin LingualSpray, metered400 ug/1SublingualWilshire Pharmaceuticals, Inc.2011-02-01Not applicableUs
Nitroject Inj 1mg/mlLiquid1 mgIntravenousOmega Laboratories Ltd1990-12-31Not applicableCanada
Nitroject Inj 5mg/mlLiquid5 mgIntravenousOmega Laboratories Ltd1988-12-31Not applicableCanada
Nitrol (nitroglycerin Ointment 2%, USP)Ointment2 %TopicalPaladin Labs Inc1985-12-31Not applicableCanada
NitrolingualSpray400 ug/1OralRebel Distributors Corp1985-10-312016-12-07Us
NitrolingualSpray400 ug/1OralEspero Pharmaceuticals, Inc.2016-03-01Not applicableUs
Nitrolingual PumpspraySpray, metered0.4 mgSublingualSanofi Aventis Canada Inc1998-07-31Not applicableCanada
Nitrolingual PumpspraySpray, metered400 ug/1OralArbor Pharmaceuticals, Inc.2000-02-01Not applicableUs
Nitrolingual Spray 0.4mg/eamAerosol, metered0.4 mgSublingualAventis Pharma Inc1986-12-312001-07-20Canada
NitromistAerosol, metered400 ug/1SublingualAkrimax Pharmaceuticals, LLC2010-05-01Not applicableUs
NitromistAerosol, metered400 ug/1SublingualMist Pharmaceuticals, Llc2016-01-25Not applicableUs
Nitrong SR Srt 2.6mgTablet, extended release2.6 mgOralMetro Pharm Inc.1964-12-312005-09-15Canada
NitrostatTablet.4 mg/1SublingualCardinal Health2000-05-01Not applicableUs
NitrostatTablet.4 mg/1OralGeneral Injectables & Vaccines, Inc2010-03-01Not applicableUs
NitrostatTablet.4 mg/1SublingualA S Medication Solutions Llc2000-05-01Not applicableUs
NitrostatTablet.6 mg/1SublingualParke Davis Div Of Pfizer Inc2000-05-01Not applicableUs
NitrostatTablet.4 mg/1OralPhysicians Total Care, Inc.1995-08-11Not applicableUs
NitrostatTablet.4 mg/1SublingualAidarex Pharmaceuticals LLC2000-05-01Not applicableUs
NitrostatTablet.4 mg/1SublingualA S Medication Solutions Llc2000-05-01Not applicableUs
NitrostatTablet.3 mg/1OralPhysicians Total Care, Inc.1994-09-22Not applicableUs
NitrostatTablet.4 mg/1SublingualPreferred Pharmaceuticals, Inc.2013-05-15Not applicableUs
NitrostatTablet.4 mg/1SublingualREMEDYREPACK INC.2012-03-022016-10-26Us
NitrostatTablet.4 mg/1SublingualA S Medication Solutions Llc2000-05-01Not applicableUs
NitrostatTablet.3 mg/1SublingualParke Davis Div Of Pfizer Inc2000-05-01Not applicableUs
NitrostatTablet.4 mg/1SublingualREMEDYREPACK INC.2013-05-13Not applicableUs
NitrostatTablet.4 mg/1SublingualRebel Distributors Corp2000-05-01Not applicableUs
NitrostatTablet.4 mg/1SublingualParke Davis Div Of Pfizer Inc2000-05-01Not applicableUs
NitrostatTablet.4 mg/1SublingualA S Medication Solutions Llc2000-05-01Not applicableUs
NitrostatTablet.4 mg/1SublingualSina Health Inc2000-05-01Not applicableUs
Nitrostat Slt 0.3mgTablet0.3 mgSublingualPfizer Canada Inc1972-12-31Not applicableCanada
Nitrostat Slt 0.6mgTablet0.6 mgSublingualPfizer Canada Inc1972-12-31Not applicableCanada
RectivOintment4 mg/gRectalAptalis Pharma US, Inc.2011-06-21Not applicableUs
RectivOintment4 mg/gRectalPro Strakan, Inc.2011-06-21Not applicableUs
Rho-nitro PumpspraySpray, metered0.4 mgSublingualSandoz Canada Incorporated2001-12-20Not applicableCanada
Transderm-nitro 0.2Patch, extended release25 mgTransdermalNovartis Pharmaceuticals Canada Inc1989-12-31Not applicableCanada
Transderm-nitro 0.4Patch, extended release50 mgTransdermalNovartis Pharmaceuticals Canada Inc1989-12-31Not applicableCanada
Transderm-nitro 0.6Patch, extended release75 mgTransdermalNovartis Pharmaceuticals Canada Inc1994-12-31Not applicableCanada
Transderm-nitro 0.8Patch, extended release100 mgTransdermalNovartis Pharmaceuticals Canada Inc1994-12-311999-08-04Canada
Tridil Injection 5mg/mlLiquid5 mgIntravenousDupont Pharma Inc.1993-12-312001-08-07Canada
Trinipatch 0.2Patch22.4 mgTransdermalPaladin Labs Inc1999-04-01Not applicableCanada
Trinipatch 0.4Patch44.8 mgTransdermalPaladin Labs Inc1999-04-01Not applicableCanada
Trinipatch 0.6Patch67.2 mgTransdermalPaladin Labs Inc1999-04-01Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-nitroglycerinSpray, metered0.4 mgSublingualApotex Inc2013-09-23Not applicableCanada
MinitranPatch18 mg/1TransdermalValeant Pharmaceuticals North America LLC2012-02-21Not applicableUs
MinitranPatch2.5 mg/dTransdermalGraceway Pharmaceuticals, LLC2007-04-01Not applicableUs
MinitranPatch36 mg/1TransdermalValeant Pharmaceuticals North America LLC2012-02-21Not applicableUs
MinitranPatch5 mg/dTransdermalGraceway Pharmaceuticals, LLC2007-04-01Not applicableUs
MinitranPatch54 mg/1TransdermalValeant Pharmaceuticals North America LLC2012-02-21Not applicableUs
MinitranPatch10 mg/dTransdermalGraceway Pharmaceuticals, LLC2009-08-10Not applicableUs
MinitranPatch9 mg/1TransdermalValeant Pharmaceuticals North America LLC2012-02-21Not applicableUs
MinitranPatch15 mg/dTransdermalGraceway Pharmaceuticals, LLC2007-04-01Not applicableUs
Nitro-bidOintment20 mg/gTopicalE. FOUGERA & CO., A division of Nycomed US Inc.2009-08-15Not applicableUs
Nitro-bidOintment20 mg/gTopicalSavage Laboratories a division of Fougera Pharmaceuticals Inc.2009-08-15Not applicableUs
NitroglycerinTablet.4 mg/1SublingualDr. Reddys Laboratories Inc2016-08-29Not applicableUs
NitroglycerinPatch.6 mg/hTransdermalMylan Pharmaceuticals Inc.1996-08-30Not applicableUs
NitroglycerinTablet.3 mg/1SublingualIngenus Pharmaceuticals Nj, Llc2016-08-26Not applicableUs
NitroglycerinTablet.6 mg/1SublingualDr. Reddys Laboratories Inc2016-08-29Not applicableUs
NitroglycerinInjection, solution5 mg/mLIntravenousCardinal Health2003-03-04Not applicableUs
NitroglycerinPatch.1 mg/hTransdermalMylan Pharmaceuticals Inc.1998-06-18Not applicableUs
NitroglycerinInjection, solution5 mg/mLIntravenousAmerican Regent, Inc.2003-03-04Not applicableUs
NitroglycerinPatch.2 mg/hTransdermalMylan Pharmaceuticals Inc.1996-08-30Not applicableUs
NitroglycerinTablet.6 mg/1SublingualIngenus Pharmaceuticals Nj, Llc2016-08-26Not applicableUs
NitroglycerinFilm, extended release20.8 mg/1TransdermalKremers Urban Pharmaceuticals Inc.2004-08-10Not applicableUs
NitroglycerinFilm, extended release37.4 mg/1TransdermalKremers Urban Pharmaceuticals Inc.2004-08-10Not applicableUs
NitroglycerinPatch.4 mg/hTransdermalMylan Pharmaceuticals Inc.1996-08-30Not applicableUs
NitroglycerinTablet.4 mg/1SublingualIngenus Pharmaceuticals Nj, Llc2016-08-26Not applicableUs
NitroglycerinTablet.3 mg/1SublingualDr. Reddys Laboratories Inc2016-08-29Not applicableUs
Nitroglycerin ERCapsule2.5 mg/1OralPd Rx Pharmaceuticals, Inc.2010-05-10Not applicableUs
Nitroglycerin ERCapsule6.5 mg/1OralPd Rx Pharmaceuticals, Inc.2010-05-10Not applicableUs
Nitroglycerin ERCapsule9 mg/1OralPd Rx Pharmaceuticals, Inc.2010-05-10Not applicableUs
Nitroglycerin In DextroseInjection, solution400 ug/mLIntravenousHospira, Inc.1990-08-31Not applicableUs
Nitroglycerin In DextroseInjection, solution200 ug/mLIntravenousHospira, Inc.1990-08-31Not applicableUs
Nitroglycerin In DextroseInjection, solution100 ug/mLIntravenousHospira, Inc.1990-08-31Not applicableUs
Nitroglycerin LingualSpray400 ug/1OralPerrigo New York Inc2013-09-20Not applicableUs
Nitroglycerin Transdermal Delivery SystemPatch.4 mg/hTransdermalAlvogen, Inc.2010-11-10Not applicableUs
Nitroglycerin Transdermal Delivery SystemPatch2.5 mg/dTransdermalGraceway Pharmaceuticals, LLC2007-04-01Not applicableUs
Nitroglycerin Transdermal Delivery SystemPatch.6 mg/hTransdermalAlvogen, Inc.2010-11-10Not applicableUs
Nitroglycerin Transdermal Delivery SystemPatch5 mg/dTransdermalGraceway Pharmaceuticals, LLC2007-04-01Not applicableUs
Nitroglycerin Transdermal Delivery SystemPatch10 mg/dTransdermalPhysicians Total Care, Inc.2004-10-27Not applicableUs
Nitroglycerin Transdermal Delivery SystemPatch.1 mg/hTransdermalAlvogen, Inc.2010-11-10Not applicableUs
Nitroglycerin Transdermal Delivery SystemPatch10 mg/dTransdermalGraceway Pharmaceuticals, LLC2007-04-04Not applicableUs
Nitroglycerin Transdermal Delivery SystemPatch5 mg/dTransdermalPhysicians Total Care, Inc.2004-10-12Not applicableUs
Nitroglycerin Transdermal Delivery SystemPatch.2 mg/hTransdermalAlvogen, Inc.2010-11-10Not applicableUs
Nitroglycerin Transdermal Delivery SystemPatch15 mg/dTransdermalGraceway Pharmaceuticals, LLC2007-04-01Not applicableUs
Nitroglycerin Transdermal Delivery SystemPatch2.5 mg/dTransdermalPhysicians Total Care, Inc.2006-05-30Not applicableUs
Nitroglycerin Transdermal SystemPatch.2 mg/hTransdermalCardinal Health1998-10-30Not applicableUs
Nitroglycerin Transdermal SystemPatch.6 mg/hTransdermalHercon Laboratories Corporation1998-10-30Not applicableUs
Nitroglycerin Transdermal SystemPatch.2 mg/hTransdermalHarvard Drug Group, LLC1998-10-30Not applicableUs
Nitroglycerin Transdermal SystemPatch.4 mg/hTransdermalHarvard Drug Group, LLC1998-10-30Not applicableUs
Nitroglycerin Transdermal SystemPatch.2 mg/hTransdermalHercon Laboratories Corporation1998-10-30Not applicableUs
Nitroglycerin Transdermal SystemPatch.6 mg/hTransdermalHarvard Drug Group, LLC1998-10-30Not applicableUs
Nitroglycerin Transdermal SystemPatch.4 mg/hTransdermalHercon Laboratories Corporation1998-10-30Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nitro-timeCapsule2.5 mg/1OralMajor Pharmaceuticals2004-01-29Not applicableUs
Nitro-timeCapsule2.5 mg/1OralTIME CAP LABORATORIES, INC2014-06-19Not applicableUs
Nitro-timeCapsule6.5 mg/1OralMajor Pharmaceuticals2004-01-29Not applicableUs
Nitro-timeCapsule9 mg/1OralCarilion Materials Management2004-01-29Not applicableUs
Nitro-timeCapsule6.5 mg/1OralTIME CAP LABORATORIES, INC2014-06-19Not applicableUs
Nitro-timeCapsule9 mg/1OralMajor Pharmaceuticals2004-01-29Not applicableUs
Nitro-timeCapsule2.5 mg/1OralCarilion Materials Management2004-01-29Not applicableUs
Nitro-timeCapsule9 mg/1OralTIME CAP LABORATORIES, INC2014-06-19Not applicableUs
Nitro-timeCapsule6.5 mg/1OralCarilion Materials Management2004-01-29Not applicableUs
NitroglycerinTablet.4 mg/1OralPreferred Pharmaceuticals, Inc2005-03-03Not applicableUs
NitroglycerinInjection, solution5 mg/mLIntravenousGENERAL INJECTABLES AND VACCINES, INC.2010-06-01Not applicableUs
NitroglycerinTablet.4 mg/1OralRebel Distributors Corp2005-03-03Not applicableUs
Nitroglycerin ERCapsule6.5 mg/1OralAv Kare, Inc.2012-12-19Not applicableUs
Nitroglycerin ERCapsule2.5 mg/1OralAv Kare, Inc.2012-12-19Not applicableUs
Nitroglycerin SlocapsCapsule6.5 mg/1OralRebel Distributors Corp1982-08-25Not applicableUs
Nitroglycerin SlocapsCapsule2.5 mg/1OralRebel Distributors Corp1982-08-25Not applicableUs
International Brands
NameCompany
DeponitUCB Pharma
DermatransBayer
Gen-NitroGenpharm ULC
GlytrinSanofi-Aventis
Glytrin SpraySanofi-Aventis
NatisprayTeofarma
NitrocapOrion
Nitroderm TTSNovartis
Nitrolingual Pump SprayArbor Pharmaceuticals
RectogesicProStrakan
StangylNot Available
Transderm-NitroNovartis
TridilNot Available
TrimonitSanofi-Aventis
TrinipatchPaladin
TriniplasNovartis
TrinispraySanofi Aventis
Trinitrin Simplex LaleufSanofi
TrinitronQuesada
TrinitrosanMerck
TrintekGoldshield
TrocerIncepta
Trocer SRIncepta
VasolatorSanwa Kagaku
VasovinTorrent
VenitrinMeda
VerniesParke Davis
WilllongWill-Pharma
Brand mixtures
NameLabellerIngredients
Nitroglycerin In 5% Dextrose Inj.-100mcg/mlBaxter Corporation
Nitroglycerin In 5% Dextrose Inj.-200mcg/mlBaxter Corporation
Nitroglycerin In 5% Dextrose Inj.-400mcg/mlBaxter Corporation
SaltsNot Available
Categories
UNIIG59M7S0WS3
CAS number55-63-0
WeightAverage: 227.0865
Monoisotopic: 227.002578773
Chemical FormulaC3H5N3O9
InChI KeySNIOPGDIGTZGOP-UHFFFAOYSA-N
InChI
InChI=1S/C3H5N3O9/c7-4(8)13-1-3(15-6(11)12)2-14-5(9)10/h3H,1-2H2
IUPAC Name
1,3-bis(nitrooxy)propan-2-yl nitrate
SMILES
[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O
Pharmacology
IndicationFor the prevention of angina
Structured Indications
PharmacodynamicsNitroglycerin, an organic nitrate, is available in many forms as a vasodilator. Nitroglycerin is used in the treatement of angina pectoris and perioperative hypertension, to produce controlled hypotension during surgical procedures, to treat hypertensive emergencies, and to treat congestive heart failure associated with myocardial infarction.
Mechanism of actionSimilar to other nitrites and organic nitrates, nitroglycerin is converted to nitric oxide (NO), an active intermediate compound which activates the enzyme guanylate cyclase. This stimulates the synthesis of cyclic guanosine 3',5'-monophosphate (cGMP) which then activates a series of protein kinase-dependent phosphorylations in the smooth muscle cells, eventually resulting in the dephosphorylation of the myosin light chain of the smooth muscle fiber. The subsequent release of calcium ions results in the relaxation of the smooth muscle cells and vasodilation.
TargetKindPharmacological actionActionsOrganismUniProt ID
Atrial natriuretic peptide receptor 1Proteinyes
agonist
HumanP16066 details
Related Articles
AbsorptionNot Available
Volume of distribution
  • 3 L/kg
Protein bindingNot Available
Metabolism

Hepatic, cytochrome P450 (P450) is a key enzyme of organic nitrate biotransformation

Route of eliminationNot Available
Half life3 minutes
Clearance
  • 1 L/kg/min
ToxicityIncreased intracranial pressure, with any or all of persistent throbbing headache, confusion, and moderate fever; Vertigo; Palpitations; Visual disturbances; Nausea and vomiting (possibly with colic and even bloody diarrhea); Syncope (especially in the upright posture); Air hunger and dyspnea, later followed by reduced ventilatory effort; Diaphoresis, with the skin either flushed or cold and clammy; Heart block and bradycardia; Paralysis; Coma; Seizures; Death.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcebutololThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Acebutolol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Acetazolamide.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitroglycerin.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Nitroglycerin.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Aliskiren.Approved, Investigational
AlteplaseThe serum concentration of Alteplase can be decreased when it is combined with Nitroglycerin.Approved
AmifostineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Nitroglycerin.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nitroglycerin.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Nitroglycerin.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Amyl Nitrite.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Apraclonidine.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Nitroglycerin.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Nitroglycerin.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Azilsartan medoxomil.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Nitroglycerin.Experimental
BarbitalBarbital may increase the hypotensive activities of Nitroglycerin.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Nitroglycerin.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Nitroglycerin.Approved
BepridilThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Nitroglycerin.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nitroglycerin.Approved
BortezomibThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Bortezomib.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Nitroglycerin.Approved
BromocriptineBromocriptine may decrease the vasodilatory activities of Nitroglycerin.Approved, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Bupivacaine.Approved, Investigational
CabergolineCabergoline may decrease the vasodilatory activities of Nitroglycerin.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Candesartan.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Carbetocin.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Nitroglycerin.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Carvedilol.Approved, Investigational
ChlorothiazideThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nitroglycerin.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Cilnidipine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Nitroglycerin.Approved
ClozapineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Conivaptan.Approved, Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Nitroglycerin.Investigational
DapsoneThe risk or severity of adverse effects can be increased when Dapsone is combined with Nitroglycerin.Approved, Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Desflurane.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nitroglycerin.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Diclofenamide.Approved
DihydroergotamineDihydroergotamine may decrease the vasodilatory activities of Nitroglycerin.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Nitroglycerin.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Dipyridamole.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Nitroglycerin.Approved
DuloxetineNitroglycerin may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Nitroglycerin.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Enalaprilat.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Nitroglycerin.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Eprosartan.Approved
Ergoloid mesylateErgoloid mesylate may decrease the vasodilatory activities of Nitroglycerin.Approved
ErgonovineErgonovine may decrease the vasodilatory activities of Nitroglycerin.Approved
ErgotamineErgotamine may decrease the vasodilatory activities of Nitroglycerin.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Nitroglycerin.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Etacrynic acid.Approved
EthanolEthanol may increase the vasodilatory activities of Nitroglycerin.Approved
FelodipineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Felodipine.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Fenoldopam.Approved
FimasartanThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Fimasartan.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nitroglycerin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Nitroglycerin.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Guanfacine.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Halothane.Approved, Vet Approved
HeparinNitroglycerin may decrease the anticoagulant activities of Heparin.Approved, Investigational
HexobarbitalHexobarbital may increase the hypotensive activities of Nitroglycerin.Approved
HydralazineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Hydroflumethiazide.Approved
IloprostThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Indapamide.Approved
IndoraminThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Indoramin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Nitroglycerin.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Nitroglycerin.Approved
LacidipineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Lacidipine.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Levobupivacaine.Approved
LevodopaNitroglycerin may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Levosimendan.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nitroglycerin.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Lofexidine.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Nitroglycerin.Approved
MannitolThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Mannitol.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nitroglycerin.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Nitroglycerin.Approved
MethohexitalMethohexital may increase the hypotensive activities of Nitroglycerin.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nitroglycerin.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Methyldopa.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Nitroglycerin.Approved
MetipranololThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Nitroglycerin.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Nitroglycerin.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Nitroglycerin.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Nitroglycerin.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Nitroglycerin.Approved
MorphineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Morphine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Moxonidine.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Nadolol.Approved
NebivololThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Nebivolol.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Nesiritide.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Nitroglycerin.Approved
NicorandilNicorandil may increase the hypotensive activities of Nitroglycerin.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Nifedipine.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Nitroglycerin.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Nitroglycerin.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Nitroglycerin.Approved
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Nitroglycerin.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Obinutuzumab.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nitroglycerin.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Oxprenolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Paclitaxel.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Papaverine.Approved
PenbutololThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Nitroglycerin.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Perindopril.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Phenelzine.Approved
PhenobarbitalPhenobarbital may increase the hypotensive activities of Nitroglycerin.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Phentolamine.Approved
PindololThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Pipamperone.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Nitroglycerin.Approved
PrilocaineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Prilocaine.Approved
PrimidonePrimidone may increase the hypotensive activities of Nitroglycerin.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Nitroglycerin.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Quinapril.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Nitroglycerin.Approved
RasagilineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Remifentanil.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Nitroglycerin.Approved
RiociguatNitroglycerin may increase the hypotensive activities of Riociguat.Approved
RisperidoneNitroglycerin may increase the hypotensive activities of Risperidone.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Ropivacaine.Approved
RosiglitazoneThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Rosiglitazone.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Sacubitril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Nitroglycerin.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Selegiline.Approved, Investigational, Vet Approved
SevofluraneThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the vasodilatory activities of Nitroglycerin.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Nitroglycerin.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Nitroglycerin.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Sufentanil.Approved, Investigational
TadalafilTadalafil may increase the vasodilatory activities of Nitroglycerin.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Tamsulosin.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Telmisartan.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Terazosin.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Nitroglycerin.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Nitroglycerin.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Thioridazine.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Nitroglycerin.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Nitroglycerin.Approved
TolazolineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Tolcapone.Approved, Withdrawn
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Nitroglycerin.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nitroglycerin.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Tranylcypromine.Approved
TretinoinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Nitroglycerin.Approved
UdenafilUdenafil may increase the vasodilatory activities of Nitroglycerin.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Nitroglycerin.Approved, Investigational
VardenafilVardenafil may increase the vasodilatory activities of Nitroglycerin.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Nitroglycerin.Approved
Food Interactions
  • Avoid alcohol.
  • Dissolve under the tongue.
  • Take on empty stomach: 1 hour before or 2 hours after meals.
References
Synthesis Reference

Izhak Blank, “Nitroglycerin preparations.” U.S. Patent US4482534, issued December, 1979.

US4482534
General ReferencesNot Available
External Links
ATC CodesC01DA52C05AE01C01DA02
AHFS Codes
  • 24:12.08
  • 92:02.00*
PDB EntriesNot Available
FDA labelDownload (801 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7613
Blood Brain Barrier+0.9113
Caco-2 permeable-0.5775
P-glycoprotein substrateNon-substrate0.8322
P-glycoprotein inhibitor INon-inhibitor0.671
P-glycoprotein inhibitor IINon-inhibitor0.9005
Renal organic cation transporterNon-inhibitor0.8325
CYP450 2C9 substrateNon-substrate0.8982
CYP450 2D6 substrateNon-substrate0.9022
CYP450 3A4 substrateNon-substrate0.5255
CYP450 1A2 substrateNon-inhibitor0.8022
CYP450 2C9 inhibitorNon-inhibitor0.7789
CYP450 2D6 inhibitorNon-inhibitor0.9106
CYP450 2C19 inhibitorNon-inhibitor0.72
CYP450 3A4 inhibitorNon-inhibitor0.9173
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8638
Ames testAMES toxic0.9107
CarcinogenicityCarcinogens 0.6822
BiodegradationReady biodegradable0.9479
Rat acute toxicity2.9173 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.512
hERG inhibition (predictor II)Non-inhibitor0.9382
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novadel pharma inc
  • Pohl boskamp
  • Graceway pharmaceuticals llc
  • Key pharmaceuticals inc sub schering plough corp
  • Hercon laboratories corp
  • Kremers urban co
  • Mylan technologies inc
  • Novartis pharmaceuticals corp
  • G pohl boskamp gmbh and co
  • Sanofi aventis us llc
  • Abraxis pharmaceutical products
  • Hospira inc
  • International medication systems ltd
  • Luitpold pharmaceuticals inc
  • Smith and nephew solopak div smith and nephew
  • Baxter healthcare corp
  • Rorer pharmaceutical corp sub rorer group
  • Parke davis div warner lambert co
  • E fougera div altana inc
  • Pfizer pharmaceuticals ltd
Packagers
Dosage forms
FormRouteStrength
PowderSublingual400 ug/g
PatchTransdermal10 mg/d
PatchTransdermal15 mg/d
PatchTransdermal18 mg
PatchTransdermal18 mg/1
PatchTransdermal2.5 mg/d
PatchTransdermal36 mg
PatchTransdermal36 mg/1
PatchTransdermal5 mg/d
PatchTransdermal54 mg/1
PatchTransdermal54 mg
PatchTransdermal9 mg/1
PatchTransdermal72 mg
Patch, extended releaseTransdermal20.7 mg
Patch, extended releaseTransdermal41.4 mg
Patch, extended releaseTransdermal62.2 mg
Patch, extended releaseTransdermal82.9 mg
Aerosol, meteredSublingual0.4 mg
OintmentTopical20 mg/g
PatchTransdermal120 mg/1
PatchTransdermal160 mg/1
PatchTransdermal20 mg/1
PatchTransdermal40 mg/1
PatchTransdermal60 mg/1
PatchTransdermal80 mg/1
Patch, extended releaseTransdermal40 mg
Patch, extended releaseTransdermal60 mg
Patch, extended releaseTransdermal80 mg
Patch, extended releaseTransdermal120 mg
Patch, extended releaseTransdermal160 mg
CapsuleOral2.5 mg/1
CapsuleOral6.5 mg/1
CapsuleOral9 mg/1
Tablet, extended releaseBuccal1 mg
Film, extended releaseTransdermal20.8 mg/1
Film, extended releaseTransdermal37.4 mg/1
Injection, solutionIntravenous5 mg/mL
PatchTransdermal.1 mg/h
PatchTransdermal.2 mg/h
PatchTransdermal.4 mg/h
PatchTransdermal.6 mg/h
TabletOral.4 mg/1
Tablet, orally disintegratingSublingual.3 mg/1
Tablet, orally disintegratingSublingual.4 mg/1
Tablet, orally disintegratingSublingual.6 mg/1
SolutionIntravenous
InjectionIntravenous10 mg/100mL
InjectionIntravenous20 mg/100mL
InjectionIntravenous40 mg/100mL
Injection, solutionIntravenous100 ug/mL
Injection, solutionIntravenous200 ug/mL
Injection, solutionIntravenous400 ug/mL
SolutionIntravenous5 mg
Spray, meteredSublingual400 ug/1
LiquidIntravenous1 mg
LiquidIntravenous5 mg
OintmentTopical2 %
SprayOral400 ug/1
Spray, meteredOral400 ug/1
Spray, meteredSublingual0.4 mg
Aerosol, meteredSublingual400 ug/1
Tablet, extended releaseOral2.6 mg
TabletOral.3 mg/1
TabletSublingual.3 mg/1
TabletSublingual.4 mg/1
TabletSublingual.6 mg/1
TabletSublingual0.3 mg
TabletSublingual0.6 mg
OintmentRectal4 mg/g
Patch, extended releaseTransdermal25 mg
Patch, extended releaseTransdermal50 mg
Patch, extended releaseTransdermal75 mg
Patch, extended releaseTransdermal100 mg
PatchTransdermal22.4 mg
PatchTransdermal44.8 mg
PatchTransdermal67.2 mg
Prices
Unit descriptionCostUnit
Nitrolingual 0.4 mg/spray Solution 12 gm Bottle242.83USD bottle
Nitrolingual 0.4 mg/spray Solution 4.9 gm Bottle141.43USD bottle
Nitro-Dur 30 0.6 mg/hr Patches Box130.86USD box
Nitro-Dur 30 0.8 mg/hr Patches Box130.86USD box
Nitro-Dur 30 0.3 mg/hr Patches Box120.68USD box
Nitro-Dur 30 0.4 mg/hr Patches Box117.1USD box
Minitran 30 0.6 mg/hr Patches Box114.01USD box
Nitro-Dur 30 0.1 mg/hr Patches Box106.09USD box
Nitro-Dur 30 0.2 mg/hr Patches Box105.6USD box
Minitran 30 0.4 mg/hr Patches Box105.18USD box
Minitran 30 0.2 mg/hr Patches Box93.86USD box
Minitran 30 0.1 mg/hr Patches Box92.36USD box
Nitroglycerin 30 0.6 mg/hr Patches Box63.55USD box
Nitroglycerin 5 mg/ml kit62.38USD kit
Nitroglycerin 30 0.4 mg/hr Patches Box57.62USD box
Nitroglycerin 30 0.2 mg/hr Patches Box50.44USD box
Nitrostat 100 0.4 mg Sublingual Tabs Bottle29.88USD bottle
Nitromist 400 mcg spray28.5USD g
Nitrostat 100 0.3 mg Sublingual Tabs Bottle27.75USD bottle
Nitrostat 100 0.6 mg Sublingual Tabs Bottle24.99USD bottle
Nitroglycerin 100 0.6 mg Sublingual Tabs Bottle23.99USD bottle
Nitroglycerin 100 0.3 mg Sublingual Tabs Bottle22.99USD bottle
Nitrostat 25 0.4 mg Sublingual Tabs Bottle19.31USD bottle
Nitroglycerin 25 0.4 mg Sublingual Tabs Bottle9.5USD bottle
Nitro-dur 0.6 mg/hr patch4.19USD patch
Nitro-dur 0.8 mg/hr patch4.19USD patch
Nitro-dur 0.3 mg/hr patch3.87USD patch
Nitro-dur 0.4 mg/hr patch3.87USD patch
Minitran 0.6 mg/hr patch3.51USD patch
Nitro-dur 0.2 mg/hr patch3.45USD patch
Nitro-dur 0.1 mg/hr patch3.4USD patch
Minitran 0.4 mg/hr patch3.24USD patch
Minitran 0.2 mg/hr patch2.89USD patch
Minitran 0.1 mg/hr patch2.84USD patch
Nitroglycerin CR 6.5 mg capsule1.66USD capsule
Nitroglycerin 0.1 mg/hr Patches1.64USD patch
Nitroglycerin CR 9 mg capsule1.27USD capsule
Nitro-Dur 0.8 0.8 mg/hr Patch1.16USD patch
Nitroglycerin er 9 mg capsule1.0USD capsule
Transderm-Nitro 0.4 0.4 mg/hr Patch0.81USD patch
Transderm-Nitro 0.6 0.6 mg/hr Patch0.81USD patch
Minitran 0.4 0.4 mg/hr Patch0.74USD patch
Minitran 0.6 0.6 mg/hr Patch0.74USD patch
Nitroglycerin er 6.5 mg capsule0.72USD capsule
Transderm-Nitro 0.2 0.2 mg/hr Patch0.71USD patch
Nitro-Dur 0.4 0.4 mg/hr Patch0.67USD patch
Nitro-Dur 0.6 0.6 mg/hr Patch0.67USD patch
Trinipatch 0.4 0.4 mg/hr Patch0.67USD patch
Trinipatch 0.6 0.6 mg/hr Patch0.67USD patch
Minitran 0.2 0.2 mg/hr Patch0.66USD patch
Nitrol 2 % Ointment0.64USD g
Nitro-Dur 0.2 0.2 mg/hr Patch0.59USD patch
Trinipatch 0.2 0.2 mg/hr Patch0.59USD patch
Nitroglycerin 9 mg capsule sa0.53USD capsule
Nitro-bid 2% ointment0.48USD g
Nitroglycerin CR 2.5 mg capsule0.47USD capsule
Nitro-time er 9 mg capsule0.37USD capsule
Nitroglycerin 0.4 mg tablet sl0.36USD tablet
Nitrostat 0.4 mg tablet sl0.35USD tablet
Nitro-time er 6.5 mg capsule0.33USD capsule
Nitro-time er 2.5 mg capsule0.29USD capsule
Nitroglycerin er 2.5 mg capsule0.28USD capsule
Nitroglycerin 6.5 mg capsule sa0.22USD capsule
Nitroquick 0.3 mg tablet sl0.19USD tablet
Nitroglycerin 2.5 mg capsule sa0.18USD capsule
Nitroglycerin 2% ointment0.17USD g
Nitrostat 0.6 mg tablet sl0.16USD tablet
Nitroglycerin 0.3 mg tablet sl0.14USD tablet
Nitroglycerin 0.6 mg tablet sl0.14USD tablet
Nitrostat 0.3 mg Sublingual Tablet0.13USD tablet
Nitrostat 0.6 mg Sublingual Tablet0.13USD tablet
Nitrolingual Pumpspray 0.4 mg/dose Metered Dose Spray0.08USD dose
Nitroquick 0.4 mg tablet sl0.08USD tablet
Nitroquick 0.6 mg tablet sl0.08USD tablet
Nitrostat 0.3 mg tablet sl0.07USD tablet
Mylan-Nitro 0.4 mg/dose Metered Dose Spray0.04USD dose
Ntg 25 mg/250 ml in d5w0.04USD ml
Rho-Nitro Pumpspray 0.4 mg/dose Metered Dose Spray0.04USD dose
Ntg 50 mg/500 ml in d5w0.02USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5186938 No1993-02-162010-02-16Us
US5869082 No1996-04-162016-04-16Us
US6500456 No1998-09-162018-09-16Us
US7872049 No2008-03-142028-03-14Us
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point13.5 °CPhysProp
boiling point250 °CPhysProp
water solubility1380 mg/L (at 20 °C)SEIDELL,A (1941)
logP1.62HANSCH,C ET AL. (1995)
logS-2.22ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.204 mg/mLALOGPS
logP1.25ALOGPS
logP0.94ChemAxon
logS-3ALOGPS
pKa (Strongest Basic)-5.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area165.15 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity40.6 m3·mol-1ChemAxon
Polarizability15.56 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.71 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as nitrate esters. These are compounds containing a nitrate ester functional group, with the general structure RON+(=O)O, (R cannot be a hydrogen).
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassOrganic nitric acids and derivatives
Sub ClassNitrate esters
Direct ParentNitrate esters
Alternative Parents
Substituents
  • Alkyl nitrate
  • Organic nitrate
  • Nitrate ester
  • Organic nitro compound
  • Organic 1,3-dipolar compound
  • Allyl-type 1,3-dipolar organic compound
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Organic zwitterion
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein kinase activity
Specific Function:
Receptor for the atrial natriuretic peptide NPPA/ANP and the brain natriuretic peptide NPPB/BNP which are potent vasoactive hormones playing a key role in cardiovascular homeostasis. Has guanylate cyclase activity upon binding of the ligand.
Gene Name:
NPR1
Uniprot ID:
P16066
Molecular Weight:
118918.11 Da
References
  1. Madhani M, Scotland RS, MacAllister RJ, Hobbs AJ: Vascular natriuretic peptide receptor-linked particulate guanylate cyclases are modulated by nitric oxide-cyclic GMP signalling. Br J Pharmacol. 2003 Aug;139(7):1289-96. [PubMed:12890708 ]
  2. Bauersachs J: Aminoethyl nitrate--the novel super nitrate? Br J Pharmacol. 2009 Sep;158(2):507-9. doi: 10.1111/j.1476-5381.2009.00414.x. [PubMed:19732062 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Electron carrier activity
Specific Function:
Not Available
Gene Name:
ALDH2
Uniprot ID:
P05091
Molecular Weight:
56380.93 Da
References
  1. Badejo AM Jr, Hodnette C, Dhaliwal JS, Casey DB, Pankey E, Murthy SN, Nossaman BD, Hyman AL, Kadowitz PJ: Mitochondrial aldehyde dehydrogenase mediates vasodilator responses of glyceryl trinitrate and sodium nitrite in the pulmonary vascular bed of the rat. Am J Physiol Heart Circ Physiol. 2010 Sep;299(3):H819-26. doi: 10.1152/ajpheart.00959.2009. Epub 2010 Jun 11. [PubMed:20543077 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 02:39